Skip to main content
SpringerLink
Log in

B-Cell-Targeted Therapies in Sjögren’s Syndrome

  • Chapter
  • First Online:
Sjögren’s Syndrome

  • 1198 Accesses

Abstract

B-cell hyperactivity has been recognized for a long time in Sjögren’s syndrome (SS). More than 30 years ago, Talal et al. demonstrated an increased level of beta-2-microglobulin in the serum of patients with SS [1]. More than 20 years ago, Moutsopoulos et al. detected increased levels of immunoglobulin light chains within the sera of patients with SS [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Talal N, Grey HM, Zvaifler N, et al. Elevated salivary and synovial fluid beta2-microglobulin in Sjogren’s syndrome and rheumatoid arthritis. Science. 1975;187:1196–8.

    Article  PubMed  CAS  Google Scholar 

  2. Moutsopoulos HM, Steinberg AD, Fauci AS, et al. High incidence of free monoclonal lambda light chains in the sera of patients with Sjogren’s syndrome. J Immunol. 1983;130(6):2663–5.

    PubMed  CAS  Google Scholar 

  3. Ioannidis JP, Vassiliou VA, Moutsopoulos HM. Long-term risk of mortality and ­lymphoproliferative disease and predictive classification of primary Sjogren’s syndrome. Arthritis Rheum. 2002;46:741–7.

    Article  PubMed  Google Scholar 

  4. Kassan SS, Thomas TL, Moutsopoulos H, et al. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978;89:888–92.

    PubMed  CAS  Google Scholar 

  5. Theander E, Henriksson G, Ljungberg O, et al. Lymphoma and other malignancies in primary Sjogren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann Rheum Dis. 2006;65:796–803.

    Article  PubMed  CAS  Google Scholar 

  6. Zinteras E, Voulgarelis M, Moutsopoulos HM. The risk of lymphoma development in autoimmune diseases: a meta-analysis. Arch Intern Med. 2005;165:2337–44.

    Article  Google Scholar 

  7. Royer B, Cazals-Hatem D, Sibilia J, et al. Lymphomas in patients with Sjögren’s syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites and are not associated with viruses. Blood. 1997;90:766–75.

    PubMed  CAS  Google Scholar 

  8. Voulgarelis M, Dafni UG, Isenberg DA, et al. Malignant lymphoma in primary Sjogren’s syndrome: a multicenter, retrospective, clinical study by the European Concerted Action on Sjogren’s Syndrome. Arthritis Rheum. 1999;42:1765–72.

    Article  PubMed  CAS  Google Scholar 

  9. Bende RJ, Aarts WM, Riedl RG, et al. Among B cell non-Hodgkin’s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med. 2005;201:1229–41.

    Article  PubMed  CAS  Google Scholar 

  10. Gottenberg JE, Busson M, Cohen-Solal J, et al. Correlation of serum B lymphocyte stimulator and beta2 microglobulin with autoantibody secretion and systemic involvement in primary Sjogren’s syndrome. Ann Rheum Dis. 2005;64(7):1050–5.

    Article  PubMed  Google Scholar 

  11. Gottenberg JE, Aucouturier F, Goetz J, et al. Serum immunoglobulin free light chain assessment in rheumatoid arthritis and primary Sjögren’s syndrome. Ann Rheum Dis. 2007;66(1):23–7.

    Article  PubMed  CAS  Google Scholar 

  12. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med. 1999;189:1747–56.

    Article  PubMed  CAS  Google Scholar 

  13. Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science. 1999;285:260–3.

    Article  PubMed  CAS  Google Scholar 

  14. Nardelli B, Belvedere O, Roschke V, et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood. 2001;97:198–204.

    Article  PubMed  CAS  Google Scholar 

  15. Mackay F, Woodcock SA, Lawton P, et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med. 1999;190:1697–710.

    Article  PubMed  CAS  Google Scholar 

  16. Groom J, Kalled SL, Cutler AH, et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren’s syndrome. J Clin Invest. 2002;109:59–68.

    PubMed  CAS  Google Scholar 

  17. Mariette X, Roux S, Zhang J, et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren’s syndrome. Ann Rheum Dis. 2003;62:168–71.

    Article  PubMed  CAS  Google Scholar 

  18. Jonsson M, Szodoray P, Jellestad S, et al. Association between circulating levels of the novel TNF family members APRIL and BAFF and lymphoid organization in primary Sjögren’s syndrome. J Clin Immunol. 2005;25(3):189–201.

    Article  PubMed  CAS  Google Scholar 

  19. Pers JO, Daridon C, Devauchelle V, et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann N Y Acad Sci. 2005;1050:34–9.

    Article  PubMed  CAS  Google Scholar 

  20. Pers JO, d’Arbonneau F, Devauchelle-Pensec V, et al. Is periodontal disease mediated by salivary BAFF in Sjögren’s syndrome? Arthritis Rheum. 2005;52:2411–4.

    Article  PubMed  Google Scholar 

  21. Lavie F, Miceli-Richard C, Quillard J, et al. Overexpression of BAFF in T cells infiltrating labial salivary glands from patients with Sjögren’s syndrome. J Pathol. 2004;202:496–502.

    Article  PubMed  CAS  Google Scholar 

  22. Daridon C, Devauchelle V, Hutin P, et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjögren’s syndrome. Arthritis Rheum. 2007;56:1134–44.

    Article  PubMed  CAS  Google Scholar 

  23. Ittah M, Miceli-Richard C, Gottenberg JE, et al. B-cell activating factor of the TNF family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in ­primary Sjögren’s syndrome. Arthritis Res Ther. 2006;8:R51.

    Article  PubMed  Google Scholar 

  24. Bave U, Nordmark G, Lofgren T, et al. Activation of the type-I interferon system in primary SS. Arthritis Rheum. 2005;52:1185–95.

    Article  PubMed  CAS  Google Scholar 

  25. Hjelmervik TO, Petersen K, Jonassen I, et al. Gene expression profiling of minor salivary glands clearly distinguishes primary Sjogren’s syndrome patients from healthy control subjects. Arthritis Rheum. 2005;52:1534–44.

    Article  PubMed  CAS  Google Scholar 

  26. Gottenberg J, Cagnard N, Lucchesi C, et al. Activation of interferon pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome. Proc Natl Acad Sci USA. 2006;103:2770–5.

    Article  PubMed  CAS  Google Scholar 

  27. Ittah M, Miceli-Richard C, Gottenberg JE, et al. Viruses induce high expression of B cell-activating factor by salivary gland epithelial cells through Toll-like receptor- and type-I interferon-dependent and -independent pathways. Eur J Immunol. 2008;38(4):1058–64.

    Article  PubMed  CAS  Google Scholar 

  28. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjögren’s syndrome. Results of the randomized controlled trial of Remicade in primary Sjögren’s syndrome (TRIPSS). Arthritis Rheum. 2004;50:1270–6.

    Article  PubMed  CAS  Google Scholar 

  29. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren’s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum. 2004;50:2240–5.

    Article  PubMed  CAS  Google Scholar 

  30. Mavragani CP, Niewold TB, Moutsopoulos NM, et al. Augmented interferon-alpha pathway activation in patients with Sjögren’s syndrome treated with etanercept. Arthritis Rheum. 2007;56:3995–4004.

    Article  PubMed  CAS  Google Scholar 

  31. Somer BG, Tsai DE, Downs L, et al. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum. 2003;49(3):394–8.

    Article  PubMed  Google Scholar 

  32. Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren’s syndrome-associated B-cell aggressive non-Hodgkin’s lymphomas. Rheumatology (Oxford). 2004;43(8):1050–3.

    Article  CAS  Google Scholar 

  33. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren’s syndrome. Rheumatology (Oxford). 2004;43(10):1309–10.

    Article  CAS  Google Scholar 

  34. Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren’s syndrome associated with hepatitis C virus infection. Lupus. 2004;13(12):969–71.

    Article  PubMed  Google Scholar 

  35. Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren’s syndrome and associated MALT lymphoma. Ann Rheum Dis. 2005;64(6):958–60.

    Article  PubMed  CAS  Google Scholar 

  36. Ahmadi-Simab K, Lamprecht P, Nolle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren’s syndrome with rituximab. Ann Rheum Dis. 2005;64(7):1087–8.

    Article  PubMed  CAS  Google Scholar 

  37. Ring T, Kallenbach M, Praetorius J, et al. Successful treatment of a patient with primary Sjogren’s syndrome with rituximab. Clin Rheumatol. 2006;25(6):891–4.

    Article  PubMed  Google Scholar 

  38. Voulgarelis M, Giannouli S, Tzioufas AG, et al. Long term remission of Sjogren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). Ann Rheum Dis. 2006;65(8):1033–7.

    Article  PubMed  CAS  Google Scholar 

  39. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum. 2005;52:2740–50.

    Article  PubMed  CAS  Google Scholar 

  40. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren’s syndrome. Ann Rheum Dis. 2007;66:351–7.

    Article  PubMed  CAS  Google Scholar 

  41. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjögren’s syndrome after two infusions of rituximab (anti-CD20). Arthritis Rheum. 2007;57:310–7.

    Article  PubMed  CAS  Google Scholar 

  42. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren’s syndrome with rituximab: results of a randomised, double-blind, placebo controlled pilot study. Ann Rheum Dis. 2008;67:1541–4.

    Article  PubMed  CAS  Google Scholar 

  43. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren’s syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010;62:960–8.

    Article  PubMed  CAS  Google Scholar 

  44. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009;68:25–32.

    Article  PubMed  CAS  Google Scholar 

  45. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum. 2010 Sep;62(9):2625–32.

    Google Scholar 

  46. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834–40.

    Article  PubMed  CAS  Google Scholar 

  47. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 2006;54:723–32.

    Article  PubMed  CAS  Google Scholar 

  48. Toubi E, Kessel A, Slobodin G, et al. Macrophage function changes following rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66(6):818–20.

    Article  PubMed  CAS  Google Scholar 

  49. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B-cell activating factor of the TNF family (BAFF) after rituximab: insights into a new regulating system of BAFF production. Ann Rheum Dis. 2007;66(5):700–3.

    Article  PubMed  CAS  Google Scholar 

  50. Pers JO, Devauchelle V, Daridon C, et al. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren’s syndrome. Arthritis Rheum. 2007;56:1464–77.

    Article  PubMed  Google Scholar 

  51. Steinfeld SD, Tant L, Burmester GR, et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren’s syndrome: an open-label phase I/II study. Arthritis Res Ther. 2006;8(4):R129.

    Article  PubMed  Google Scholar 

  52. Stohl W, Chatham W, Weisman M, et al. Belimumab (BmAb), a novel fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), selectively modulates B-cell sub-populations and immunoglobulins in a heterogeneous rheumatoid arthritis subject population. Arthritis Rheum. 2005;52:S444.

    Article  Google Scholar 

  53. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009;61(9):1168–78.

    Article  PubMed  CAS  Google Scholar 

  54. Navarra S, Ilianova E, Bae SC, et al. Belimumab, a blys-specific inhibitor, reduced disease activity, flares, and steroid use in patients with seropositive systemic lupus erythematosus (SLE): BLISS-52 study. EULAR 2010 meeting, poster SAT0204, Rome, 2010.

    Google Scholar 

  55. van Vollenhoven RF, Zamani O, Wallace DJ, et al. Belimumab, a blys-specific inhibitor, reduces disease activity and severe flares in seropositive sle patients: BLISS-76 study. EULAR 2010 meeting, oral presentation, Rome, 2010.

    Google Scholar 

  56. Seror R, Ravaud P, Bowman S, et al. EULAR Sjogren’s Syndrome Disease Activity Index (ESSDAI): development of a consensus systemic disease activity index in primary Sjogren’s syndrome. Ann Rheum Dis. 2010;69(6):1103–9.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris-Sud 11, Le Kremlin Bicêtre, France

    Xavier Mariette

  2. Institut Pour la Santé et la Recherche Médicale (INSERM), Paris, France

    Xavier Mariette

Authors
  1. Xavier Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Barcelona, Surgey, Hospital Clinic, Calle Villarroel, 170, Barcelona, 08036, Spain

    Manuel Ramos-Casals

  2. Massachusetts General Hospital, Boston, 02114, Massachusetts, USA

    John H. Stone

  3. National University of Athens, Athens, Greece

    Haralampos M. Moutsopoulos

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag London Limited

About this chapter

Cite this chapter

Mariette, X. (2011). B-Cell-Targeted Therapies in Sjögren’s Syndrome. In: Ramos-Casals, M., Stone, J., Moutsopoulos, H. (eds) Sjögren’s Syndrome. Springer, London. https://doi.org/10.1007/978-0-85729-947-5_40

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-947-5_40

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-946-8

  • Online ISBN: 978-0-85729-947-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation